WCG
TWST icon

Weaver Consulting Group’s Twist Bioscience TWST Stock Holding History

Weaver Consulting Group’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$15K – 844
2020
Q3 		$15K Buy
+200
New +$12.5K 0.01% 466

Other funds holding TWST

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weaver Consulting Group's TWST Position: Q4 2020 in Review

Weaver Consulting Group sold out of Twist Bioscience (TWST) in Q4 2020, closing a stake of 200 shares — an estimated $15K sold.

Weaver Consulting Group first reported a position in TWST in Q3 2020 and held it in 1 quarter. The position peaked at $15K in Q3 2020. 222 funds tracked by Wall St. Rank hold TWST as of Q4 2020.

  • Weaver Consulting Group reported no remaining Twist Bioscience position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 200 Twist Bioscience shares in Q4 2020, an estimated $15K.
  • Weaver Consulting Group first reported a position in Twist Bioscience in Q3 2020 and held it in 1 quarter.
  • Weaver Consulting Group's Twist Bioscience position peaked at $15K in Q3 2020.
  • 222 funds tracked by Wall St. Rank held Twist Bioscience as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.